• MJHLS Brand Logo

© 2021 MJH Life Sciences™ and Neurology Live. All rights reserved.

Disease Spotlight: NMOSD

EP. 1: Outer Retinal Layer Thinning Non-Factor in Retinal Damage of AQP4-IgG NMOSD

November 4th 2021

Repeated analyses using both 3-mm and 1-mm diameter macular data—narrower volumes than standard—showed no relevant outer plexiform layer or outer nuclear layer thinning in those with seropositive AQP4-IgG.

EP. 2: Priorities in NMO: Biomarkers, Therapy Discontinuation, and More With Marcelo Matiello, MD

October 28th 2021

The associate director of the Neuromyelitis Optica Clinic and Research Unit at Mass General spoke about some of the unmet needs and unanswered questions surrounding NMO management.

EP. 3: Better COVID-19 Outcomes in MOGAD Than NMOSD, Registry Data Show

October 28th 2021

Data presented at CMSC 2021 suggest worse COVID-19 outcomes were associated with patients with neuromyelitis optica spectrum disorder and other comorbidities.

EP. 4: Satralizumab Demonstrates Long-Term Safety in NMOSD

October 28th 2021

Rates of infection or serious infection with satralizumab in the overall treatment period were not higher than those on placebo in the double-blind period and did not increase over time.

EP. 5: New Sponsors, Potential Development in NMOSD: Bruce Cree, MD, PhD, MAS, FAAN

October 24th 2021

Following the approval of 3 treatments for the disease, the clinical research director of the UCSF Multiple Sclerosis Center commented on the implications for the clinical development pipeline. [WATCH TIME: 4 minutes]

EP. 6: Understanding the Value of B-Cell Depletion in NMOSD

October 23rd 2021

Jeffrey Bennett, MD, PhD, professor of neurology, University of Colorado, discussed his presentation at ECTRIMS involving the relationship of B-cell depletion and improved outcomes in patients treated with inebilizumab.

EP. 7: Eculizumab Shows Better Prolonging of Time to NMOSD Relapse Than Other Treatments

October 17th 2021

An indirect comparison study evaluated relative treatment effects of eculizumab (Soliris; Alexion), inebilizumab (Uplizna; Horizon), and satralizumab (Enspryng; Genentech), the 3 FDA-approved options for NMOSD.

EP. 8: Patient Education and Awareness in NMOSD: Bruce Cree, MD, PhD, MAS, FAAN

October 13th 2021

The clinical research director of the USCF Multiple Sclerosis Center discussed the importance of improving knowledge and education for patients with NMOSD, as well as strategies to do so. [WATCH TIME: 3 minutes]

EP. 9: Day-to-Day Care of NMOSD, Advances and Challenges: Bruce Cree, MD, PhD, MAS, FAAN

October 12th 2021

Discussing the 3 FDA-approved treatments for NMOSD, the clinical research director of the UCSF Multiple Sclerosis Center commented on the positive impact, as well as resultant barriers to care. [WATCH TIME: 4 minutes]

EP. 10: Understanding Disadvantages to African Americans in NMOSD Trials: Evanthia Bernitsas, MD

October 12th 2021

The neurologist at Wayne State University provided background on why there needs to be a continued focus on including and studying African American patients with NMOSD in trials. [WATCH TIME 3 minutes]